

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: March 22, 2018  
(Date of earliest event reported)

**REVA MEDICAL, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-54192**  
(Commission  
File Number)

**33-0810505**  
(I.R.S. Employer  
Identification No.)

**5751 Copley Drive, San Diego, CA**  
(Address of principal executive offices)

**92111**  
(Zip Code)

**(858) 966-3000**  
(Registrant's telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On March 22, 2018, R. Scott Huennekens, who is a Class II member of the board of directors of REVA Medical, Inc. (the “Company”) and whose three-year term is expiring at the Company’s 2018 annual meeting, informed the Company that he does not intend to stand for re-election at the 2018 annual meeting due to his other time commitments. Mr. Huennekens’ decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**REVA Medical, Inc.**

Date: March 26, 2018

/s/ Brandi L. Roberts

Brandi L. Roberts

Chief Financial Officer and Corporate Secretary